Found 23 matching trials
Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066) PHASE3 The primary objective of this study is the estimation of the human papillom...
Show More Location
Sotobo Children's Clinic ( Site 6616)
Learn More & Join Trial
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) PHASE3 This study will evaluate the efficacy, immunogenicity and safety of 9-valen...
Show More Status
Active Not Recruiting
Location
Lingchuan Center for Disease Control and Prevention ( Site 0002)
Learn More & Join Trial
Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009) PHASE3 Primary objective:
• To demonstrate that administration of V503 induces no...
Show More Location
Multiple Locations
Learn More & Join Trial
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females PHASE3 The study will evaluate the immunogenicity and safety of 9-valent HPV recom...
Show More Location
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
Learn More & Join Trial
HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini PHASE4 This is a multi-site, open-label non-inferiority study of the 9vHPV vaccine...
Show More Learn More & Join Trial
Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053) PHASE3 This study is designed to demonstrate non-inferior immunogenicity of 3 dose...
Show More Status
Active Not Recruiting
Location
Liucheng County Centers for Disease Control and Prevention ( Site 0005)
Learn More & Join Trial
Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064) PHASE3 The purposes of this phase 3, double-blind, placebo-controlled clinical stu...
Show More Location
Umeyama Clinic ( Site 6406)
Learn More & Join Trial
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) PHASE3 This study will evaluate the immunogenicity and tolerability of V503 (a mul...
Show More Location
Multiple Locations
Learn More & Join Trial
Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years PHASE3 The purpose of the study is to demonstrate the non-inferiority (NI) of the ...
Show More Learn More & Join Trial
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) PHASE3 This study is designed to evaluate the immunogenicity and tolerability of 9...
Show More Location
Multiple Locations
Learn More & Join Trial